No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Aardvark Therapeutics, Inc. Common Stock (AARD) stock was $5.09 as of Oct 6, 2026, 10:04 AM EDT, down 2.54% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -67.4%
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments.
Biotechnology · San Diego, CA
LATEST PRICE
$5.09
52-WEEK RANGE
$3.35 - $17.94
BETA
3.81
% FROM 52W HIGH
-71.64%
MARKET CAP
$111.33M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
1.49
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.01
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
-67.36%
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.74
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.66
vs Estimate
$-0.88
Revenue
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$11.11
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.04 | $-0.72 | $-0.33 | 8 |
| Quarter ending Dec 2026 | $-1.08 | $-0.72 | $-0.41 | 7 |
| Quarter ending Mar 2027 | $-0.69 | $-0.69 | $-0.69 | 2 |
| Quarter ending Jun 2027 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AARD | $111.33M | $5.09 | -2.54% | -67.36% | N/A | N/A | N/A |
| 2IMUX | $110.88M | $8.14 | +0.86% | -17.41% | -35.70% | -43.80% | vs AARD |
| 3BDTX | $109.73M | $1.92 | -1.29% | -49.96% | -24.47% | N/A | vs AARD |
| 4BGM | $109.24M | $8.61 | -7.91% | -96.69% | N/A | N/A | vs AARD |
| 5LUCD | $113.78M | $0.60 | +0.52% | -42.80% | N/A | N/A | vs AARD |
| 6APYX | $108.64M | $2.58 | -0.77% | -10.07% | -28.10% | N/A | vs AARD |
+118.4% upside
Low
$3.00
Current
$5.09
High
$28.00
| $-0.61 |
| $-0.61 |
| $-0.61 |
| 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.80 | $-3.15 | $-2.46 | 9 |
| FY 2027 | $-3.62 | $-2.56 | $-1.84 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $300000.00 | $300000.00 | $300000.00 | 9 |
| FY 2027 | $1.03M | $1.03M | $1.03M | 6 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
